摘要 |
The present invention provides radioactive metal heterocomplexes of formula (I): [(Me-N-R)L<SUB>1</SUB>L<SUB>2</SUB>]+Z. (I), wherein Me, R, L<SUP>1 </SUP>L<SUP>2 </SUP>and Z<SUP>-</SUP> have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L<SUP>1</SUP>, which allows the formation of substitution-inert [(Me-N-R)L<SUP>1</SUP>] moieties. Such moieties are fixed in an intermediate [(Me-N-R)Y<SUB>2</SUB>L<SUP>1</SUP>)]<SUP>+</SUP> compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L<SUP>2 </SUP>to give the final [(Me-N-R)L<SUP>1</SUP>L<SUP>2</SUP>]<SUP>+</SUP>Z<SUP>-</SUP>heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L<SUP>2 </SUP>framework or the imido R group.
|